Orateur
Description
For many years, nuclear medicine was focus mainly on imaging using Technecium-99m. Some therapy was conducted using Iodine-131 mainly to treat thyroid cancer. In the 2000’s, positron emission tomography (PET) imaging arrived leading to a new wave of applications for nuclear medicine especially in cancer imaging using Flurodesoxyglucose labelled with fluorine-18 (18F-FDG). Several attempt to develop therapeutic agents failed to reach the market despite some efficacy as for example the Zevalin, an antibody labelled with Yttrium-90 for some lymphomas. Since 2013, the third wave of applications has started, focused on therapeutic agent using the peptide receptor radionuclide therapy and coupling imaging and therapy in the so-called theranostics approach. This has resulted in the approval of several new products for routine use including 2 therapeutic radiophamarmaceuticals labelled with Lutecium-177: 177Lu-DOTATATE for neuroendocrine tumors approved in 2018 and 177Lu-PSMA for metastatic prostate cancers (2021). This new wave uses new radionuclides for therapy such as Lutecium-177, Copper-67, Terbium-161… for targeted beta-therapy and Actinium-225, Lead-212/Bismuth-212, Astatine-211 … for targeted alpha therapy. New imaging radionuclides are also developed to be used as imaging counterparts to apply the theranostics approach using PET such as Gallium-68 or Copper-64 or using SPECT such as Lead-203 for example. In parallel, people start to explore the potential of Auger emission. For many of these radionuclides, there is not yet a consensus on the best production method and it is important to get cross section data for the radionuclide of interest but also contaminants. The technical evolution of accelerators also open wider the nuclear reaction that can be used making different projectiles available (p,d,t, electrons) and/or allowing higher energy to be used (commercial machine available up to 70 MeV). All these lead to the need of cross section data. Acknowledgements This work has been, in part, supported by a grant from the French National Agency for Research called "Investissements d'Avenir", ISITE NEXT no. ANR-16-IDEX-0007 and SIRIC ILIAD. It has also been supported partly through funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101008571 (PRISMAP).
